BioLineRx: Positive Top-Line Results from Phase 3 Multiple Myeloma Trial

 - Study met all primary and secondary endpoints with exceptionally high level of statistical significance (p<0.0001) -

- Motixafortide + G-CSF demonstrated a 4.9-fold increase versus G-CSF alone in achieving primary endpoint of target mobilization in up to TWO apheresis sessions -

- 88.3% of patients receiving Motixafortide + G-CSF underwent transplantation after only ONE apheresis session, compared to 10.8% for G-CSF alone; supports Motixafortide on top of G-CSF as new standard of care in this indication -

- Management conference call May 4, at 10:00 am EDT -

BioLineRx will hold a conference call today, Tuesday, May 4, 2021 at 10:00 a.m. EDT. To access the conference call, please dial +1-866-860-9642 from the US or +972-3-918-0644 internationally. The call will also be available via webcast and can be accessed through the Investor Relations page of BioLineRx's website. Please allow extra time prior to the call to visit the site and download any necessary software to listen to the live broadcast.

A replay of the conference call will be available for a limited time approximately two hours after completion of the live conference call on the Investor Relations page of BioLineRx's website. A dial-in replay of the call will be available until May 6, 2021; please dial +1-888-295-2634 from the US or +972-3-925-5904 internationally.

https://finance.yahoo.com/news/biolinerx-announces-positive-top-line-110000755.html